Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

Enanta Pharmaceuticals (NETA) stock fell as the company plans to appeal a court ruling favoring Pfizer in a patent dispute ...

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Judge Katharine H Parker, handling Luigi Mangione's pre-trial hearings, is married to a former Pfizer executive and holds ...

Pfizer on Tuesday forecast 2025 profit roughly in line with estimates, offering some relief to investors after the drugmaker ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...

Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...